Noxopharm is a Group comprising Noxopharm Ltd, Nyrada Inc, and NoxAsia Ltd with offices in Sydney, New York and Hong Kong. The Group's drug pipeline contains 4 drug candidates: Veyonda®, NYX-104, NYX-205, NYX-330. Veyonda® is being developed as an enhancer of radiotherapy across a range of cancers being treated with both standard external beam radiotherapy and intravenous radionuclide (177lutetium-PSMA-617) therapy; NYX-104 is a neuroprotectant being developed to limit secondary brain damage (glutamate-induced excitotoxicity) following ischaemic stroke and concussion; NYX-205 is an anti-inflammatory being developed for the treatment of peripheral neuropathy associated with diabetes and chemotherapy; NYX-330 is a PCSK9 inhibitor being developed for the treatment of high blood LDL cholesterol levels that fail to respond adequately to statin therapy alone.
Veyonda® is the first pipeline product, previously known as NOX66. It is currently in clinical trials.
We envisage a family of products that will become standard adjunctive therapies wherever any form of radiotherapy is used. The aim is to enhance the effectiveness of radiotherapy:
- allowing the dosage of radiotherapy to be lowered to a level enabling radiotherapy to be used in patients where the use of radiotherapy currently is not considered for safety reasons
- producing greater killing of cancer cells in tumours directly exposed to radiotherapy
- producing killing of cancer cells in tumours not exposed to radiotherapy (abscopal response).
Veyonda® is an innovative dosage formulation of the generic anti-cancer agent, idronoxil. Idronoxil specifically targets cancer cells, rendering them less able to survive radiotherapy.
Radiation seeks to kill cancer cells by damaging their DNA beyond any ability of the cancer cell to repair the damage. All cells have a well-developed mechanism to repair DNA damage that goes on working for about a week following the radiation. The equation is simple: if the cell is successful in repairing the damage, then it survives; if unsuccessful, then it dies.
A number of drugs have been developed seeking to block that repair mechanism, meaning more cancer cells dying after radiotherapy. No such drugs have been successful to date because they do not discriminate between repair mechanisms in cancer cells and in healthy cells. Non-discrimination means that such drugs also increase the toxic side-effects of radiotherapy, thus countering any benefit from their use.
Idronoxil is different because it only blocks repair mechanisms in cancer cells...healthy cells are unaffected. But in order to block the repair mechanism, idronoxil needs to be present on a continuous basis. When it is not present, the repair process is allowed to continue unabated. That means that idronoxil, to be fully effective, needs to be present for 24 hours a day for at least a week following the radiotherapy.
Previous attempts to use idronoxil in cancer patients led to it being quickly eliminated from the body after about 1 hour. That meant that there were long periods each day when repair activity was able to continue unchecked. In those circumstances, idronoxil was unable to deliver a meaningful anti-cancer effect.
That problem has been overcome with Veyonda®. Veyonda® is a proprietary formulation that has been developed specifically to keep idronoxil in the body in an active form for long periods of time. A single suppository dosing is intended to provide an effective level of idronoxil in the body for up to 24 hours. Veyonda® provides the means for idronoxil to exert a continuous anti-cancer effect for as many days as it is administered.
Veyonda® and Chemotherapy
Veyonda® has also been recently being trialed as an adjunct therapy to a standard of care chemotherapy drug, with the ultimate aim of increasing the sensitivity of widely-used chemotherapies while simultaneously reducing many the well-documented damaging side-effects.